Moreover, the number of predicted neoantigens correlates with clinical outcomes in melanoma and lung cancer patients undergoing anti-CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) or anti-PD-1 (Programmed cell death protein 1) immune checkpoint blockade antibody therapy [17,18,19]. The gene discussed is PDCD1; the disease is melanoma.